The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Market Size Increase Is Anticipated For The Somatostatin Analogs Market Over The 2026–2030 Period?
The somatostatin analogs market has experienced robust expansion in recent years. This market is projected to expand from $7.16 billion in 2025 to $7.66 billion by 2026, demonstrating a compound annual growth rate (CAGR) of 7.1%. Historically, this growth has been driven by factors such as the increasing diagnosis of neuroendocrine tumors, the rising prevalence of hormone disorders, compelling clinical efficacy evidence, increased specialist prescribing, and improved hospital access.
The somatostatin analogs market size is expected to show significant expansion in the coming years, with projections indicating it will reach $10.15 billion by 2030, driven by a compound annual growth rate (CAGR) of 7.3%. This anticipated growth throughout the forecast period is primarily due to factors such as the introduction of biosimilars, broader therapeutic indications, the increasing elderly demographic, better diagnostic rates, and favorable reimbursement for specialty drugs. Noteworthy trends during this period include the rising use of long-acting injectables, an increase in neuroendocrine tumor indications, a greater focus on improving patient adherence, continued biosimilar development, and an uptick in hospital-based therapy utilization.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10840&type=smp
What Drivers Are Expected To Influence The Somatostatin Analogs Market During The Forecast Period?
The somatostatin analogs market is expected to experience growth, propelled by the expanding aging population. An aging population describes a demographic shift characterized by an increased proportion or number of individuals aged 65 years and older within a society. The rise in this older demographic correlates with a greater incidence of diseases necessitating the use of Somatostatin Analogs, thereby driving demand for these pharmaceutical products. For instance, in July 2024, the UK Parliament’s House of Commons Library, a UK-based government administration, reported that in 2022, the UK had 12.7 million people aged 65 or older, constituting 19% of the total population. This figure is projected to increase to 22.1 million by 2072, representing 27% of the population. Therefore, the growing aging population is a key driver for the expansion of the somatostatin analogs market.
How Is The Somatostatin Analogs Market Segmented Across Key Categories?
The somatostatin analogs market covered in this report is segmented –
1) By Type: Octreotide, Lanreotide, Pasireotide
2) By Treatment: Acromegaly, Cushing’s Syndrome, Neuroendocrine Tumors, Carcinoid Syndrome, Other Treatments
3) By End User: Hospital, Pharmaceutical Companies
Subsegments:
1) By Octreotide: Long-Acting Release (LAR) Formulations, Short-Acting Formulations
2) By Lanreotide: Depot Formulations, Injectable Formulations
3) By Pasireotide: Long-Acting Injectable Formulations, Subcutaneous Formulations
Which Market Trends Are Creating New Opportunities In The Somatostatin Analogs Market?
Major companies in the somatostatin analogs market are prioritizing the development of advanced offerings, such as targeted radiopharmaceuticals, to enhance the precision and effectiveness of cancer treatments, especially for patients with somatostatin receptor-positive tumors. These specialized drugs combine radiation-emitting isotopes with molecules designed to specifically bind to cancer cells, ensuring precise delivery of therapeutic radiation to tumor sites while minimizing exposure to healthy surrounding tissues. For instance, in January 2024, Lantheus, a US-based radiopharmaceutical-focused company, launched Lutetium Lu 177 Dotatate. Lutetium Lu-177 Dotatate is a radiolabeled somatostatin analog utilized in peptide receptor radionuclide therapy (PRRT) for the treatment of advanced somatostatin receptor-positive neuroendocrine tumors. Clinical studies have shown that it considerably improves progression-free survival and response rates when compared to traditional somatostatin analogs like octreotide, making it an essential alternative for patients whose disease has progressed despite earlier treatments. Its specific targeting mechanism enables effective tumor control with minimal systemic exposure, thereby improving the overall therapeutic profile in managing neuroendocrine malignancies.
Who Are The Dominant Players Shaping The Somatostatin Analogs Market Landscape?
Major companies operating in the somatostatin analogs market are Novartis International AG, Pfizer Inc., Sun Pharmaceutical Industries Limited, Midatech Pharma plc, Crinetics Pharmaceuticals Inc., Peptron Inc., Teva Pharmaceutical Industries Ltd., Camurus AB, Bayer Aktiengesellschaft, Cadila Healthcare Limited, Amneal Pharmaceuticals Inc., Recordati S.p.A., Amryt Pharma plc, Ipsen Pharma SA, Fresenius Kabi AG, Chiasma Inc., Merck KGaA, Sanofi S.A., Sandoz International GmbH, Takeda Pharmaceutical Company Limited, Viatris Inc., AstraZeneca plc, Johnson & Johnson, Genentech Inc., OctreoPharm Sciences GmbH
Read the full somatostatin analogs market report here:
https://www.thebusinessresearchcompany.com/report/somatostatin-analogs-global-market-report
Which Region Is Forecast To Lead The Somatostatin Analogs Market In Terms Of Market Size?
North America was the largest region in the global somatostatin analogs treatment market in 2025.Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the somatostatin analogs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Somatostatin Analogs Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=10840&type=smp
Browse Through More Reports Similar to the Global Somatostatin Analogs Market 2026, By The Business Research Company
Sorbitol Global Market Report
https://www.thebusinessresearchcompany.com/report/sorbitol-global-market-report
Aspirin Global Market Report
https://www.thebusinessresearchcompany.com/report/aspirin-global-market-report
Sorbates Global Market Report
https://www.thebusinessresearchcompany.com/report/sorbates-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model